ReShape Lifesciences presented pre-clinical data on its Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium. The device, using Hypoglycemia Vagus Nerve Stimulation (HVNS), targets the sub-diaphragmatic posterior vagus nerve to raise blood glucose during hypoglycemic events without affecting cardiac function. This research was led by Jonathan J. Waataja, Ph.D., Director of Research at ReShape Lifesciences.
This targeted neuromodulation approach is a potential game-changer for diabetes management. Current vagal stimulation methods often cause undesirable cardiac side effects, limiting their therapeutic application. This new technology addresses this critical limitation, offering a potentially safer and more effective way to manage hypoglycemia and improve the lives of individuals with diabetes. Furthermore, the sub-diaphragmatic approach avoids speech impairment, another common drawback of traditional vagus nerve stimulation. This precision targeting could broaden the therapeutic window and improve patient comfort and compliance.
In a Type 1 diabetic swine model, the implanted device successfully raised blood glucose and glucagon levels without impacting heart rate. Following insulin-induced hypoglycemia, HVNS increased blood glucose levels significantly within 30 minutes. Importantly, heart rate remained stable during stimulation. Vomiting only occurred at higher current amplitudes than those required for therapeutic benefit, indicating a manageable safety profile.
This pre-clinical data supports further development of this technology. ReShape Lifesciences aims to secure non-dilutive funding and collaborate with researchers and industry partners to bring this novel therapeutic to market. This device holds promise for reducing reliance on injections and wearable glucose monitors, ultimately improving the quality of life for people with Type 1 and Type 2 diabetes. While ReShape Lifesciences has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., which includes the Diabetes Neuromodulation system, the continued development and potential commercialization of this technology suggests a commitment to advancing diabetes care. Further research and clinical trials will be crucial to validate these pre-clinical findings and determine the long-term efficacy and safety of this promising approach.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
